Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma
04 nov. 2021 07h00 HE
|
Chimerix, Inc.
– Blinded Independent Central Review (BICR) of ONC201 Cohort Reported 20.0% Objective Response Rate (ORR) by RANO-HGG Criteria – – Compelling Durability of Responses with 11.2 Month Median Duration...
Chimerix to Present at Credit Suisse 30th Annual Healthcare Conference
01 nov. 2021 08h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Report Third Quarter 2021 Financial Results and Provide an Operational Update on November 4, 2021
28 oct. 2021 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing medicines for patients facing deadly diseases that meaningfully improves and extends...
Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update
05 août 2021 07h00 HE
|
Chimerix, Inc.
– Received U.S. Food and Drug Administration (FDA) Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox – – Blinded Independent Central Review (BICR) of ONC201 Registration Cohort in...
Chimerix to Present at 2021 Wedbush PacGrow Healthcare Conference
03 août 2021 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021
29 juil. 2021 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox
04 juin 2021 14h10 HE
|
Chimerix, Inc.
DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Present at Jefferies Virtual Healthcare Conference
25 mai 2021 08h00 HE
|
Chimerix, Inc.
DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Announces Upcoming Presentations at the American Society of Clinical Oncology 2021 Annual Meeting
19 mai 2021 17h01 HE
|
Chimerix, Inc.
DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...